GlassScriptPhysician profile
Michael A Schneider
NPI 1801885629
$8,754.89
in general payments reported to CMS, 2019-2025
27 companies · $1,130 in 2025
The $1,130 reported for 2025 was less than what a typical Clinical & Laboratory Dermatological Immunology provider received nationally (typical 2025 total: $1,130).
See the full distribution for Clinical & Laboratory Dermatological Immunology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $841 · 2021: $1,642 · 2022: $1,481 · 2023: $1,108 · 2024: $1,417 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.30 |
| Education | $188.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,618.81 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,056.90 | 2020-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $998.02 | 2020-2025 | Ilumya |
| Lilly USA, LLC | $808.99 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $725.76 | 2019-2025 | |
| Genzyme Corporation | $499.36 | 2020-2025 | |
| Leo Pharma INC. | $286.60 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $271.52 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $182.95 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $147.27 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $141.16 | 2021-2025 | Dupixent |
| Incyte Corporation | $140.72 | 2021 | |
| Sandoz INC. | $119.59 | 2019-2024 | Hyrimoz |
| Biofrontera INC. | $113.47 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $109.49 | 2023-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $106.34 | 2019-2025 | Xtrac |
| E.R. Squibb & Sons, L.L.C. | $90.34 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $81.81 | 2022-2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $69.79 | 2020-2023 | Valchlor |
| Genentech USA, INC. | $46.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.77 | 2024-2025 | Spevigo |
| Dermira, INC. | $24.56 | 2019 | |
| Mayne Pharma Commercial LLC | $24.24 | 2023 | |
| Mission Pharmacal Company | $16.12 | 2019 | |
| Organogenesis INC. | $12.86 | 2023 | Puraply |
| Nabriva Therapeutics, Plc | $12.16 | 2022 | |
| Organon LLC | $8.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.